Davenport & CO LLC Biogen Inc. Transaction History

Davenport & CO LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$190.52 - $236.72 $68,777 - $85,455	-361 Reduced 23.05%	1,205 $279,000
Q1 2024 May 03, 2024	BUY	$212.02 - $267.71 $59,365 - $74,958	280 Added 21.77%	1,566 $337,000
Q4 2023 Jan 23, 2024	SELL	$222.59 - $267.94 $16,471 - $19,827	-74 Reduced 5.44%	1,286 $332,000
Q3 2023 Oct 17, 2023	BUY	$253.3 - $285.89 $76,496 - $86,338	302 Added 28.54%	1,360 $349,000
Q2 2023 Jul 20, 2023	BUY	$275.25 - $318.06 $291,214 - $336,507	1,058 New	1,058 $301,000
Q4 2020 Jan 13, 2021	SELL	$236.26 - $355.63 $197,513 - $297,306	-836 Closed	0 $0
Q3 2020 Oct 15, 2020	BUY	$264.77 - $305.71 $221,347 - $255,573	836 New	836 $237,000
Q1 2020 May 05, 2020	SELL	$268.85 - $341.04 $334,718 - $424,594	-1,245 Closed	0 $0
Q4 2019 Jan 22, 2020	BUY	$220.06 - $304.07 $273,974 - $378,567	1,245 New	1,245 $369,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.